This page shows the latest Tobi Podhaler news and features for those working in and with pharma, biotech and healthcare.
ranibizumab). Novartis has also won the cost-effectiveness watchdog's backing in 2013 for the Tobi Podhaler (tobramycin), a treatment for cystic fibrosis.
The limited recommendation takes into account that the Tobi Podhaler and Colobreathe are dry powder versions of already available nebulised products. ... form. The Tobi Podhaler should only be used in cystic fibrosis patients for whom nebulised
Novartis’ Tobi Podhaler and Forest’s Colobreathe recommended at discounted price. Novartis' Tobi Podhaler and Forest Laboratories' Colobreathe have both received backing for use in the NHS in England and Wales ... The final draft guidance from the
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Mylan has enhanced its respiratory portfolio with the acquisition of Novartis’s TOBI Podhaler and TOBI solution, both products for treating Pseudomonas aeruginosa infections in cystic fibrosis patients. ... Licensing &. research. collaboration. $550m.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Formerly known as Packer Forbes Communications, Four Health Communications is an award-winning, integrated healthcare communications agency for pharma, biotech, NGOs...